Highlights and Quick Summary
- EBITDA Margin for the quarter ending November 30, 2022 was 25.07% (a -796.39% decrease compared to previous quarter)
- Year-over-year quarterly EBITDA Margin decreased by -366.7%
- Annual EBITDA Margin for 2022 was -12.51% (a -83.71% decrease from previous year)
- Annual EBITDA Margin for 2021 was -76.79% (a -47.75% decrease from previous year)
- Annual EBITDA Margin for 2020 was -146.96% (a -921.46% decrease from previous year)
- Twelve month EBITDA Margin ending November 30, 2022 was -0.15% (a -98.8% decrease compared to previous quarter)
- Twelve month trailing EBITDA Margin decreased by -99.37% year-over-year
Trailing EBITDA Margin for the last four month:
| 30 Nov '22 | 31 Aug '22 | 31 May '22 | 28 Feb '22 |
|---|---|---|---|
| -0.15% | -12.51% | -19.81% | -23.65% |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBITDA Margin of Organigram Holdings Inc.
Most recent EBITDA Marginof OGI including historical data for past 10 years.Interactive Chart of EBITDA Margin of Organigram Holdings Inc.
Organigram Holdings Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | 25.07% | -3.6% | -15.4% | -9.4% | -12.51% |
| 2021 | -25.2% | -32.89% | -31.91% | -163.19% | -76.79% |
| 2020 | -118.69% | -199.36% | -526.0% | 1.3% | -146.96% |
| 2019 | 13.97% | -152.31% | -36.81% | 0.0% | 17.89% |
| 2018 | – | – | 385.37% | 100.0% | 368.78% |
| 2017 | – | – | – | – | -151.72% |
| 2016 | – | – | – | – | 28.5% |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic